ABSTRACT
Objectives Proxy measures of chronic inflammation derived from DNA methylation (DNAm) data have emerged as promising predictors of cardiometabolic disease risk in high income countries. This study investigates the performance of a recently validated DNAm-based measure of C-reactive protein (DNAm-CRP) in two generations of adults in the Philippines to evaluate its utility in lower and middle income settings experiencing high levels of endemic infections as well as rising rates of chronic degenerative diseases.
Methods DNAm-CRP was calculated from 1,468 CpG sites on the Infinium MethylationEPIC v1.0 array applied to genomic DNA from leukocytes in young adults (N=1,665; 20-22 years) and older women (N=1,070; 35-68 years). C-reactive protein was determined in plasma using a high sensitivity immunoturbidimetric assay. Pearson correlation and least squares regression were implemented to evaluate the strength of association between DNAm-CRP and plasma CRP, and to investigate patterns of association between DNAm-CRP and established predictors of chronic inflammation.
Results For younger adults, the correlation between DNAm-CRP and log-transformed CRP was 0.41, and DNAm-CRP explained 17.2% of the variance in CRP. For older women, the correlation was 0.47, with 22.7% explained variance in CRP. For both cohorts larger waist circumference was associated with higher DNAm-CRP. The presence of infectious symptoms at the time of blood collection and leukocyte composition were both significant predictors of DNAm-CRP.
Conclusions In two generations of adults in the Philippines, we document strong correlations between DNAm-CRP and plasma CRP. DNAm-CRP may be a useful tool for research on chronic inflammation across a range of epidemiological and ecological settings globally, but future applications should consider how recent infections and the distribution of leukocyte subsets may confound or mediate associations of interest.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was funded by the National Institute on Aging of the National Institutes of Health (R01 AG061006R21)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data were collected under conditions of informed consent with institutional review board approval from the University of North Carolina at Chapel Hill and Northwestern University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.